NZ251525A - 1-phenyl-2-oxopyrido [2,3-d]pyrimidine derivatives and pharmaceutical compositions - Google Patents

1-phenyl-2-oxopyrido [2,3-d]pyrimidine derivatives and pharmaceutical compositions

Info

Publication number
NZ251525A
NZ251525A NZ251525A NZ25152593A NZ251525A NZ 251525 A NZ251525 A NZ 251525A NZ 251525 A NZ251525 A NZ 251525A NZ 25152593 A NZ25152593 A NZ 25152593A NZ 251525 A NZ251525 A NZ 251525A
Authority
NZ
New Zealand
Prior art keywords
pyrido
formula
compound
pyrimidine
dione
Prior art date
Application number
NZ251525A
Other languages
English (en)
Inventor
Robert Stephen Wilhelm
Ronnie Lipp Chin
Bruce Henry Devens
Robert Alvarez
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of NZ251525A publication Critical patent/NZ251525A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ251525A 1992-03-20 1993-03-18 1-phenyl-2-oxopyrido [2,3-d]pyrimidine derivatives and pharmaceutical compositions NZ251525A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/855,179 US5264437A (en) 1992-03-20 1992-03-20 Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones

Publications (1)

Publication Number Publication Date
NZ251525A true NZ251525A (en) 1996-09-25

Family

ID=25320543

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ251525A NZ251525A (en) 1992-03-20 1993-03-18 1-phenyl-2-oxopyrido [2,3-d]pyrimidine derivatives and pharmaceutical compositions

Country Status (16)

Country Link
US (1) US5264437A (forum.php)
EP (2) EP0631580A1 (forum.php)
JP (1) JP3241384B2 (forum.php)
KR (1) KR100274104B1 (forum.php)
CN (1) CN1040327C (forum.php)
AU (1) AU669520B2 (forum.php)
CA (1) CA2132297C (forum.php)
FI (1) FI106960B (forum.php)
HU (2) HUT67552A (forum.php)
IL (1) IL105092A (forum.php)
MX (1) MX9301530A (forum.php)
NO (1) NO301763B1 (forum.php)
NZ (1) NZ251525A (forum.php)
TW (1) TW240226B (forum.php)
WO (1) WO1993019068A1 (forum.php)
ZA (1) ZA931945B (forum.php)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996006843A1 (fr) * 1994-08-29 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive de naphtyridine et composition medicinale a base de ce derive
EP0804192A1 (de) * 1995-02-10 1997-11-05 Schering Aktiengesellschaft Pharmazeutische präparate zur tnf-inhibition
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
JP2000119272A (ja) 1998-10-15 2000-04-25 Nippon Zoki Pharmaceut Co Ltd 新規７−アミノピリド〔２，３−ｄ〕ピリミジン誘導体
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
TR200201317T2 (tr) 1999-08-21 2002-11-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Sinerjistik kombinasyon.
TWI243055B (en) 2000-04-13 2005-11-11 Nippon Zoki Pharmaceutical Co Pharmaceutical composition for use in treatment of dermatitis
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
ATE375331T1 (de) * 2001-11-01 2007-10-15 Janssen Pharmaceutica Nv Amidderivate als inhibitoren der glycogensynthasekinase-3-beta
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
WO2008032162A1 (en) * 2006-09-15 2008-03-20 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
TW200835497A (en) * 2007-01-11 2008-09-01 Astrazeneca Ab Chemical compounds 636
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
WO2008084236A1 (en) * 2007-01-11 2008-07-17 Astrazeneca Ab Chemical compounds 635 : pyridopyrimidinediones as pde4 inhibitors
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
FR2921926B1 (fr) * 2007-10-03 2009-12-04 Sanofi Aventis Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.
EP2778156B8 (en) 2008-05-27 2017-02-22 AstraZeneca AB Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
FR2944282B1 (fr) 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
EP3972599A1 (en) 2019-05-21 2022-03-30 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
US20240400560A1 (en) * 2021-09-17 2024-12-05 Shionogi & Co., Ltd. Bicyclic heterocyclic derivative having viral growth inhibitory activity and pharmaceutical composition containing same
CN113831491B (zh) * 2021-09-30 2023-03-24 南昌大学 一种嘧啶唑共价有机框架的制备方法及吸附应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5649917B2 (forum.php) * 1973-12-18 1981-11-25
JPS58428B2 (ja) * 1974-07-05 1983-01-06 ヒサミツセイヤク カブシキガイシヤ シンキナ ２− オキソ −１，２，３，４− テトラヒドロピリド （ ２，３−ｄ ） ピリミジンユウドウタイノ セイゾウホウ
DE2523730A1 (de) * 1974-06-12 1976-02-12 Hisamitsu Pharmaceutical Co Pyrido eckige klammer auf 2,3-d eckige klammer zu pyrimidinonen
ES2031513T3 (es) * 1986-08-21 1992-12-16 Pfizer Inc. Quinazolindionas y piridopirimidinadionas.
CA2133442A1 (en) * 1992-04-29 1993-11-11 James R. Piper Deazaaminopterins for treatment of inflammation

Also Published As

Publication number Publication date
CN1040327C (zh) 1998-10-21
KR100274104B1 (ko) 2000-12-15
HU9402653D0 (en) 1994-11-28
CN1078470A (zh) 1993-11-17
CA2132297C (en) 2006-01-03
NO943456L (no) 1994-09-16
JP3241384B2 (ja) 2001-12-25
FI944305A0 (fi) 1994-09-16
NO943456D0 (no) 1994-09-16
HUT67552A (en) 1995-04-28
FI106960B (fi) 2001-05-15
AU669520B2 (en) 1996-06-13
US5264437A (en) 1993-11-23
FI944305L (fi) 1994-09-16
ZA931945B (en) 1994-09-18
IL105092A0 (en) 1993-07-08
WO1993019068A1 (en) 1993-09-30
JPH07504676A (ja) 1995-05-25
IL105092A (en) 1998-06-15
HU210873A9 (en) 1995-08-28
TW240226B (forum.php) 1995-02-11
KR950700909A (ko) 1995-02-20
EP1770093A1 (en) 2007-04-04
EP0631580A1 (en) 1995-01-04
AU3918693A (en) 1993-10-21
CA2132297A1 (en) 1993-09-30
MX9301530A (es) 1994-01-31
NO301763B1 (no) 1997-12-08

Similar Documents

Publication Publication Date Title
NZ251525A (en) 1-phenyl-2-oxopyrido [2,3-d]pyrimidine derivatives and pharmaceutical compositions
JP3245165B2 (ja) ピリドピリダジノンおよびピリダジンチオン化合物
US5455252A (en) Optionally substituted 6,8-quinolines
US5466697A (en) 8-phenyl-1,6-naphthyridin-5-ones
US10206909B2 (en) 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10604512B2 (en) 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
US10285983B2 (en) 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
US10285982B2 (en) 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US20040072858A1 (en) Heterocyclic ether substituted imidazoquinolines
TWI643850B (zh) 作為呼吸道融合病毒之抗病毒劑的新穎經雜環取代之１，３－二氫－２ｈ－苯并咪唑－２－酮衍生物
CA2935867A1 (en) Heteroaryls and uses thereof
US20180228780A1 (en) 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
TW201927792A (zh) 作為溴結構域蛋白質抑制劑的化合物和組合物
KR20030070050A (ko) 헤테로시클릭 에테르 치환 이미다조퀴놀린
AU2009262156A1 (en) 5- and 6-membered heterocyclic compounds
KR20030008151A (ko) 이미다조피리딘 및 이미다조피리미딘 항바이러스제
US5716954A (en) Benzopyridazinone and pyridopyridazinone compounds
KR101064227B1 (ko) 피라졸로나프티리딘 유도체
JP2000063275A (ja) 医薬組成物

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)